^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    DRP®-Stenoparib CDx

    Company:
    Allarity Therap
    Type:
    Laboratory Developed Test
    Related tests:

    Details

    Evidence
    News
    The DRP®-Stenoparib CDx is a transcriptomic signature comprising 414 mRNA biomarkers that are collectively predictive of tumor sensitivity or resistance to stenoparib. Using the DRP® CDx to select likely responder patients while excluding likely resistant ones, the benefit-risk ratio of stenoparib in metastatic or locally advanced ovarian cancer can be improved.
    Cancer:
    Ovarian Cancer
    Drug:
    stenoparib (2X-121)